Posted On: 09/16/2014 11:51:56 PM
Post# of 30067
Re: Daveludlow #6466
We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro); - See more at: http://www.thechairmansblog.com/amarantus-bio...NsPUN.dpuf
Guess what LP-002 was just completed
We are continuing to evaluate shareholder value creating arrangements for our diagnostics division, including a potential ‘spin-out’ or other business arrangements that would make strategic sense for the various LymPro and Amarantus stakeholders. We will not be giving additional details related to those possible arrangements in today’s business update call, as we are contractually prohibited from doing so.
- See more at: http://www.thechairmansblog.com/amarantus-bio...qiS8U.dpuf
Also why can't they speak of the spin off? What contract does not allow them to discuss this or other business arrangements?
Guess what LP-002 was just completed
We are continuing to evaluate shareholder value creating arrangements for our diagnostics division, including a potential ‘spin-out’ or other business arrangements that would make strategic sense for the various LymPro and Amarantus stakeholders. We will not be giving additional details related to those possible arrangements in today’s business update call, as we are contractually prohibited from doing so.
- See more at: http://www.thechairmansblog.com/amarantus-bio...qiS8U.dpuf
Also why can't they speak of the spin off? What contract does not allow them to discuss this or other business arrangements?
(0)
(0)
